Neurogene Inc. NGNE 深 滬
等待開盤 07-07 09:30:00 美东时间
32.56
-2.780
-7.87%
華盛通- 最 高36.035
- 今 開35.23
- 成交量 23.02万股
- 最 低 32.42
- 昨 收 35.34
- 總市值 6.28亿
- 52周最高 37.2659
- 市盈率 靜 --
- 換手率 1.19%
- 52周最低 15.93
- 委 比 -5.99%
- 總股本 1930.19万
- 歷史最高 362.60
- 量 比 0.51
- 振 幅 10.23%
- 歷史最低 6.875
- 每 手 1
- 風險率 4.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neurogene bolsters cash runway with equity offering
An update from Neurogene ( ($NGNE) ) is now available. On June 30, 2026, Neurog...
07-02 18:28
Neurogene prices $125M equity offering
Neurogene (NGNE) priced a public offering of 3.5M common shares at $30.00 per share and 666,666 pre-funded warrants in lieu of common stock for certain investors. The pre-funded warrants are exercisab...
07-01 19:19
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offerin...
07-01 19:04
Neurogene Reveals Proposed Public Offering; No Size Disclosed
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain invest...
07-01 04:02
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett Syndrome
47 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant, and al...
06-29 19:17
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome
Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome communityNGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg
06-08 19:31
Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.36) by 2.21 percent. This is a 28.7 percent decrease over losses of $(1.08) per share from the
05-13 05:06
美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元
今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元
04-07 11:53
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $200 to $180.
04-06 23:13
